Alkeus Pharmaceuticals

In Cambridge, Massachusetts, where biotech ambition tends to speak in quiet confidence and billion dollar outcomes, Alkeus Pharmaceuticals is playing a longer game with higher stakes. Founded in 2010 by Leonide Saad, Ph.D. and Ilyas Washington, Ph.D., the company was built on a single, sharp conviction that blindness in children is not a fate to accept but a problem to solve at the molecular level. That conviction now sits in late stage development, staring down a finish line that has never existed before for Stargardt disease.

Stargardt is not subtle. It starts early, moves steadily, and ends in legal blindness with no approved treatment anywhere in the world. The culprit is a mutation in the ABCA4 gene that turns vitamin A against the eye itself, creating toxic buildup that destroys photoreceptors. Alkeus does not chase symptoms. It goes upstream. Its lead therapy, gildeuretinol acetate, is a selectively deuterated form of vitamin A designed to slow that toxic chemistry without disrupting vision itself. One daily oral dose. No surgical theater. No repeated injections. Just a quiet intervention where the damage begins.

The science traces back to Ilyas Washington, Ph.D., whose discovery reframed vitamin A from necessary nutrient to modifiable risk factor. Leonide Saad, Ph.D. saw the opening, licensed the molecule, and built Alkeus around it with the discipline of both an engineer and an operator. That origin story still shows up in how the company moves today. Focused. Lean. Relentless about data.

And the data has started to talk. Across the TEASE clinical program in Stargardt disease and the SAGA study in Geographic Atrophy, gildeuretinol has demonstrated reductions in lesion growth and signals of preserved vision over time. Regulators are listening. The FDA has granted Breakthrough Therapy, Orphan Drug, Rare Pediatric Disease, and Fast Track designations, stacking the deck for speed without lowering the bar. An NDA submission is in motion, and if it lands, this becomes the first approved treatment for a disease that has never had one.

The leadership bench reflects that moment. Michel Dahan, CEO, stepped in during 2024 with a track record of scaling companies from early stage to commercial reality. Leonide Saad, Ph.D. now drives the science as Chief Scientific Officer. David Arkowitz, M.B.A., CFO brings financial discipline. Seemi Khan, M.D., M.P.H., M.B.A., Chief Development and Strategy Officer, shapes the path forward, while Carlos Quezada Ruiz, M.D., F.A.S.R.S., Chief Medical Officer anchors the clinical vision. This is a team built for translation, not theory.

Backed by a $150M Series B led by Bain Capital Life Sciences with support from Wellington Management, TCGX, and Sofinnova, Alkeus is no longer proving it belongs. It is preparing to deliver. The opportunity stretches beyond a single indication, with Stargardt disease and Geographic Atrophy sharing the same underlying mechanism, giving one molecule the chance to matter twice.

Inside the company, the tone is clear. One team. High urgency. No wasted motion. This is what pre launch looks like when the stakes are measured in sight. They are hiring across commercial, medical, regulatory, and operations as they build toward first prescription. The door is open for people who want their work to show up in someone else’s ability to see.

Follow the story. Reach out if you build in biotech, care about rare disease, or know what it means to turn a decade of science into a single moment that changes everything.